8-K: IDEAYA Biosciences Director Susan L. Kelley to Step Down from Board, Transition to Advisory Role

Susan L. Kelley, M.D., will not seek re-election to IDEAYA Biosciences' Board of Directors and will transition to chair the company's new Clinical Advisory Board.

Summary

• On March 28, 2025, Susan L. Kelley, M.D., notified IDEAYA Biosciences, Inc. of her decision to not stand for re-election to the Board of Directors at the 2025 annual meeting of stockholders.
• Dr. Kelley will resign from the Board at the end of her current term, concluding immediately after the Annual Meeting.
• She will transition into an advisory role as Chair of the company's new Clinical Advisory Board, expected to be established before the Annual Meeting.
• The company anticipates decreasing the size of the Board to seven directors after the Annual Meeting.
• Dr. Kelley's decision is not due to any disagreement with the company's operations, policies, or practices.

Sentiment

Score: 7

Explanation: The announcement is neutral to slightly positive. The transition of a board member to an advisory role is generally viewed as a positive way to retain expertise. There is no indication of negative sentiment or disagreement.

Positives

• Dr. Kelley's transition to Chair of the Clinical Advisory Board ensures continued expertise and guidance for IDEAYA Biosciences.
• The establishment of a Clinical Advisory Board could enhance the company's clinical development strategy.
• The reduction in board size could streamline decision-making processes.

Future Outlook

The company anticipates decreasing the size of the Board to seven directors effective upon the conclusion of the Annual Meeting and establishing a Clinical Advisory Board prior to the Annual Meeting.

Management Comments

• The Company is pleased that Dr. Kelley has expressed her intention to transition into an advisory role as Chair of the Company's new Clinical Advisory Board.

Industry Context

Changes in board composition are common in the biotechnology industry as companies evolve and their strategic needs change. Establishing advisory boards is a typical practice to leverage external expertise.

Management Changes

Stakeholder Impact

• Shareholders: May perceive the board change as neutral to slightly positive, depending on their view of Dr. Kelley's contributions and the potential benefits of the Clinical Advisory Board.
• Employees: Unlikely to be significantly impacted by this change.
• Customers: No direct impact expected.
• Suppliers: No direct impact expected.
• Creditors: No direct impact expected.

Next Steps

• Establishment of the Clinical Advisory Board.
• Reduction of the Board size to seven directors after the Annual Meeting.
• Holding the 2025 Annual Meeting of Stockholders.

Key Dates

Keywords

Board of Directors, IDEAYA Biosciences, Susan L. Kelley, Clinical Advisory Board, Resignation, Management Change, Corporate Governance